CVS CVS Health Corporation Common Stock
NYSE · Health Care · Переглянути на SEC EDGAR ↗ закриття Жов 2, 2026 10-K/10-Q Сер 5, 2026CVS Знімок акцій Ціна, ринкова капіталізація, P/E, EPS, ROE, борг/власний капітал, діапазон 52 тижнів
CVS Графік ціни акцій Денні OHLCV з технічними індикаторами — панування, масштабування та налаштування вашого представлення
Гранулярність стовпчиків адаптується до вибраного періоду — наведіть курсор на графік, щоб побачити відкриття/максимум/мінімум/закриття для стовпчика.
| Дата екс-дивіденду | Спліт | Тип |
|---|---|---|
| 07 червня 2005 р. | 2-for-1 | Прямий |
| 16 червня 1998 р. | 2-for-1 | Прямий |
| 15 березня 1989 р. | 2-for-1 | Прямий |
| 03 травня 1983 р. | 2-for-1 | Прямий |
Про CVS Health Corporation Common Stock Огляд компанії з Wikipedia
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.
History
1960s
The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.
1970s
By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.
1980s
In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.
1990s
CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.
In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.
2000s
In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.
2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.
2010s
2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.
CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.
2020s
In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.
On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.
Finances
Subsidiaries and assets
Aetna
Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.
CVS Pharmacy
CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.
MinuteClinic
MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.
CVS Caremark
CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.
CVS Media Exchange
CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.
CVS Specialty
CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.
Longs Drugs
Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.
Navarro Discount Pharmacies
Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.
Accordant
Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.
Coram
Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.
Omnicare
Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.
HealthHUB
HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.
Store brands and private label brands
CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.
Criticism and controversy
Health and Medicare fraud
In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.
The combined price to settle this dispute with the U.S. Government cost the company over $250 million.
Elensys
In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.
Trio Drugs Lawsuit
On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.
Boston prescriptions
During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.
Restatements
On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.
On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.
Pharmaceutical kickbacks
In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.
The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.
There was no admission of wrongdoing by Caremark or AdvancePCS.
CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.
Deceptive business practices
In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:
CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).
However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).
...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).
Rhode Island Senate corruption case
In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."
Privacy violations
On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).
In September 2026, CVS entered into a $20.5 million class action settlement after a lawsuit alleged that CVS disclosed customers' personal data to advertising company Criteo.
Business practices under investigation
On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.
DEA investigation into oxycodone diversion
According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".
FTC charges of deceptive pricing
On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.
Co-responsibility for opioid crisis
In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.
In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.
In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.
CFI lawsuit for consumer fraud
In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.
Abortion pill controversy
In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.
Pharmacists mistakenly cause an abortion
In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."
At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.
Animal welfare
In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.
Community involvement and philanthropy
Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.
Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.
In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).
Джерело: Wikipedia (Англійська), CC BY-SA 4.0 · Переглянути на Wikipedia ↗
10-річна ефективність Тренди виручки, чистого прибутку, маржі та EPS
Оцінка Співвідношення P/E, P/S, P/B, EV/EBITDA — акція дорога чи дешева?
| Метрика | 5-річний тренд | CVS | середнє за 5 років | Медіана аналогів | Висновок |
|---|---|---|---|---|---|
| P/E (TTM) | 22.8середнє за 5 років ≈25.5 | ≈25.5 | 23.3 | Переоцінений | |
| P/S (TTM) | 0.3середнє за 5 років ≈0.3 | ≈0.3 | 1.3 | Недооцінений | |
| P/B (MRQ) | 1.4середнє за 5 років ≈1.4 | ≈1.4 | 2.9 | Недооцінений | |
| EV / EBITDA | 10.7середнє за 5 років ≈6.1 | ≈6.1 | 11.4 | Недооцінений | |
| Ціна / FCF (TTM) | 9.4середнє за 5 років ≈9.9 | ≈9.9 | · | · | |
| Ціна / Грошовий потік (TTM) | 7.5середнє за 5 років ≈7.6 | ≈7.6 | 9.8 | Справедлива вартість | |
| EV / Revenue (EV / Дохід) | 0.2середнє за 5 років ≈0.2 | ≈0.2 | · | · | |
| EV / FCF | 12.7середнє за 5 років ≈9.3 | ≈9.3 | · | · | |
| Ціна / Матеріальний чистий капітал (MRQ) | 2.0 | · | · | · |
Медіана аналогічних компаній розраховується на стандартизованій основі для кожного показника і може не завжди відповідати базі TTM/MRQ, показаній для цієї акції.
Прибутковість Валова, операційна та чиста маржа; ROE, ROA, ROIC
| Метрика | 5-річний тренд | CVS | середнє за 5 років | Медіана аналогів | Висновок |
|---|---|---|---|---|---|
| Операційна маржа (TTM) | 2.0%середнє за 5 років ≈2.8% | ≈2.8% | 8.3% | Нижче середнього | |
| Маржа EBITDA (TTM) | 3.1%середнє за 5 років ≈4.1% | ≈4.1% | 8.8% | Нижче середнього | |
| До оподаткування маржа (TTM) | 1.4%середнє за 5 років ≈2.1% | ≈2.1% | 3.8% | Відповідно | |
| Маржа чистого прибутку (TTM) | 1.2%середнє за 5 років ≈1.6% | ≈1.6% | 5.1% | Нижче середнього | |
| ROA (TTM) | 1.9%середнє за 5 років ≈2.2% | ≈2.2% | 4.0% | Слабкий | |
| ROE (TTM) | 6.2%середнє за 5 років ≈7.3% | ≈7.3% | 12.5% | Слабкий | |
| ROIC | 5.0%середнє за 5 років ≈9.6% | ≈9.6% | 9.2% | Слабкий |
Фінансове здоровʼя Борг, ліквідність, платоспроможність — міцність балансу
| Метрика | 5-річний тренд | CVS | середнє за 5 років | Медіана аналогів | Висновок |
|---|---|---|---|---|---|
| Debt / Equity (Борг / Власний капітал) | 0.0середнє за 5 років ≈0.0 | ≈0.0 | 0.4 | Низький борг | |
| Поточний коефіцієнт (MRQ) | 0.9середнє за 5 років ≈0.9 | ≈0.9 | 1.4 | Низька ліквідність | |
| Коефіцієнт швидкої ліквідності (MRQ) | 0.6середнє за 5 років ≈0.6 | ≈0.6 | 0.8 | Низька ліквідність |
Зростання Зростання виручки, EPS та чистого прибутку: рік до року, 3-річний CAGR, 5-річний CAGR
| Метрика | 5-річний тренд | CVS | середнє за 5 років | Медіана аналогів | Висновок |
|---|---|---|---|---|---|
| Revenue YoY (Виторг рік до року) | 7.8%середнє за 5 років ≈8.4% | ≈8.4% | · | · | |
| Revenue CAGR 3Y (CAGR виторгу 3 роки) | 7.6%середнє за 5 років ≈8.7% | ≈8.7% | · | · | |
| Revenue CAGR 5Y (CAGR виторгу 5 років) | 8.4% | · | · | · | |
| EPS YoY | -62.0%середнє за 5 років ≈-8.5% | ≈-8.5% | · | · | |
| Net Income YoY (Чистий прибуток рік до року) | -61.7%середнє за 5 років ≈-9.5% | ≈-9.5% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3 роки) | -24.7%середнє за 5 років ≈-11.4% | ≈-11.4% | · | · | |
| EPS CAGR 5Y (CAGR EPS 5 років) | -23.9% | · | · | · | |
| Net Income CAGR 3Y (CAGR чистого прибутку 3 роки) | -25.7%середнє за 5 років ≈-12.4% | ≈-12.4% | · | · | |
| Net Income CAGR 5Y (CAGR чистого прибутку 5 років) | -24.4% | · | · | · |
Ефективність капіталу Оборотність активів, оборотність запасів, оборотність дебіторської заборгованості
| Метрика | 5-річний тренд | CVS | середнє за 5 років | Медіана аналогів | Висновок |
|---|---|---|---|---|---|
| Asset Turnover (Оборотність активів) | 1.6середнє за 5 років ≈1.4 | ≈1.4 | 1.2 | Найвищий рівень | |
| Inventory Turnover (Оборотність запасів) | 11.8середнє за 5 років ≈11.1 | ≈11.1 | 15.6 | Нижче середнього | |
| Receivables Turnover (Оборотність дебіторської заборгованості) | 10.5середнє за 5 років ≈11.5 | ≈11.5 | 10.5 | Відповідно | |
| Revenue / Employee (Виручка / співробітник (річна виручка ÷ кількість співробітників (штатний розпис, yfinance). Похідне — не збережена концепція SEC-XBRL).) | ≈$1.8M | · | · | · |
значення · ≈ середнє за 5 років · медіана галузі · вердикт відносно медіани
Дивіденди Дивідендна дохідність, коефіцієнт виплат, історія дивідендів, 5-річний CAGR
| Дата екс-дивіденду | Сума | Валюта | Дохідність |
|---|---|---|---|
| Лип 23, 2026 | $0,67 | USD | ≈2.5% |
| Кві 23, 2026 | $0,67 | USD | ≈3.4% |
| Січ 22, 2026 | $0,67 | USD | ≈3.2% |
| Жов 23, 2025 | $0,67 | USD | ≈3.3% |
| Лип 22, 2025 | $0,67 | USD | ≈4.4% |
| Кві 22, 2025 | $0,67 | USD | ≈4.1% |
| Січ 23, 2025 | $0,67 | USD | ≈4.9% |
| Жов 21, 2024 | $0,67 | USD | ≈4.6% |
| Лип 22, 2024 | $0,67 | USD | ≈4.5% |
| Кві 19, 2024 | $0,67 | USD | ≈3.6% |
| Січ 19, 2024 | $0,67 | USD | ≈3.4% |
| Жов 19, 2023 | $0,61 | USD | ≈3.4% |
| Лип 20, 2023 | $0,61 | USD | ≈3.2% |
| Кві 20, 2023 | $0,61 | USD | ≈3.2% |
| Січ 19, 2023 | $0,61 | USD | ≈2.6% |
| Жов 20, 2022 | $0,55 | USD | ≈2.4% |
| Лип 21, 2022 | $0,55 | USD | ≈2.3% |
| Кві 21, 2022 | $0,55 | USD | ≈2.0% |
| Січ 20, 2022 | $0,55 | USD | ≈2.0% |
| Жов 21, 2021 | $0,50 | USD | ≈2.3% |
Історія прибутків EPS фактичний проти прогнозу, сюрприз %, коефіцієнт перевищення, дата наступного звіту про прибутки
| Період | Звіт | EPS (факт) | EPS прогноз | Сюрприз |
|---|---|---|---|---|
| 30 червня 2026 р. | Лип 29, 2026 | $2.58 | $1.87 | 38.0% |
| 31 березня 2026 р. | $2.57 | $2.22 | 15.8% | |
| 31 грудня 2025 р. | $1.09 | $1.00 | 8.8% | |
| 30 вересня 2025 р. | $1.60 | $1.38 | 15.7% | |
| 30 червня 2025 р. | $1.81 | $1.47 | 23.0% | |
| 31 березня 2025 р. | $2.25 | $1.72 | 30.8% |
Повні фундаментальні показники Усі показники за роками — звіт про прибутки та збитки, баланс, рух грошових коштів
Звіт про прибутки та збитки
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B | $268.71B | $256.78B | · | $184.79B | $177.55B | $153.29B | |
| Cost of Revenue | $221.17B | $206.29B | $217.10B | $196.89B | $175.80B | $163.98B | $158.72B | · | $153.45B | $146.53B | $126.76B | |
| Gross Profit | · | · | · | · | · | · | · | · | $28.55B | $28.86B | $26.53B | |
| Operating Expenses | $397.41B | $364.29B | $344.03B | $314.51B | $278.80B | $254.79B | $244.79B | · | $18.81B | $18.45B | $17.05B | |
| Operating Income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B | $13.91B | $11.99B | · | $9.54B | $10.39B | $9.47B | |
| Interest Expense | · | · | $2.66B | $2.29B | $2.50B | $2.91B | $3.04B | · | $1.06B | $1.08B | $859M | |
| Interest Income | · | · | · | · | · | · | · | · | $21M | $20M | $21M | |
| Other Non-op | $112M | $99M | $88M | $169M | $182M | $206M | $124M | · | $-208M | $-28M | · | |
| Pretax Income | $2.14B | $6.15B | $11.17B | $5.84B | $10.54B | $9.77B | $9.00B | · | $8.27B | $8.64B | $8.62B | |
| Income Tax | $408M | $1.56B | $2.81B | $1.51B | $2.55B | $2.57B | $2.37B | · | $1.64B | $3.32B | $3.39B | |
| Net Income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B | $7.18B | $6.63B | · | $6.62B | $5.32B | $5.24B | |
| EPS (Basic) | $1.40 | $3.67 | $6.49 | $3.29 | $6.07 | $5.48 | $5.10 | · | $6.47 | $4.93 | $4.66 | |
| EPS (Diluted) | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 | $5.46 | $5.08 | · | $6.44 | $4.90 | $4.63 | |
| Shares (Basic) | 1,267,000,000 | 1,259,000,000 | 1,285,000,000 | 1,312,000,000 | 1,319,000,000 | 1,309,000,000 | 1,301,000,000 | · | 1,020,000,000 | 1,073,000,000 | 1,118,000,000 | |
| Shares (Diluted) | 1,271,000,000 | 1,262,000,000 | 1,290,000,000 | 1,323,000,000 | 1,329,000,000 | 1,314,000,000 | 1,305,000,000 | · | 1,024,000,000 | 1,079,000,000 | 1,126,000,000 | |
| EBITDA | $9.27B | $13.11B | $18.11B | $11.99B | $17.70B | $18.35B | $16.36B | · | $12.00B | $10.34B | $9.45B |
Баланс
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.45B | $8.59B | $8.20B | $12.95B | $9.41B | $7.85B | $5.68B | · | $1.70B | $3.37B | $2.46B | |
| Short-term Investments | $2.15B | $2.41B | $3.26B | $2.78B | $3.12B | $3.00B | $2.37B | · | $111M | $87M | $88M | |
| Receivables | $39.78B | $36.47B | $35.23B | $27.28B | $24.43B | $21.74B | $19.62B | · | $13.18B | $12.16B | $11.89B | |
| Inventory | $19.25B | $18.11B | $18.02B | $19.09B | $17.76B | $18.50B | $17.52B | · | $15.30B | $14.76B | $14.00B | |
| Other Current Assets | $5.09B | $3.08B | $3.15B | $2.64B | $5.29B | $5.28B | $5.11B | $4.53B | $945M | $660M | $722M | |
| Current Assets | $74.71B | $68.64B | $67.86B | $65.63B | $60.01B | $56.37B | $50.30B | $45.20B | $31.23B | $31.04B | $29.16B | |
| PP&E (Net) | · | · | · | $12.87B | $12.90B | $12.61B | $12.04B | $11.36B | $10.29B | $10.18B | $9.86B | |
| PP&E (Gross) | · | · | · | $34.60B | $33.55B | $31.31B | $28.93B | · | $24.29B | $22.80B | $21.04B | |
| Accum. Depreciation | · | · | · | $21.48B | $20.65B | $18.70B | $16.89B | · | $14.00B | $12.63B | $11.18B | |
| Goodwill | $85.48B | $91.27B | $91.27B | $78.15B | $79.12B | $79.55B | $79.75B | · | $38.45B | $38.25B | $38.11B | |
| Intangibles | $25.51B | $27.32B | $29.23B | $24.80B | $29.03B | $31.14B | $33.12B | $36.31B | $13.63B | $13.51B | $13.88B | |
| Other Non-current Assets | $7.11B | $4.79B | $4.66B | $4.62B | $4.71B | $4.62B | $4.60B | $4.53B | $1.42B | $1.49B | $1.44B | |
| Total Assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B | $230.72B | $222.45B | $216.67B | $95.13B | $94.46B | $92.44B | |
| Accounts Payable | · | · | · | · | · | · | · | · | $8.86B | $7.95B | $7.49B | |
| Accrued Liabilities | $22.39B | $20.81B | $23.52B | $18.75B | $17.67B | $14.24B | $12.13B | $10.66B | $6.58B | $6.94B | $6.83B | |
| Short-term Debt | $0 | $2.12B | $200M | $0 | · | $0 | $0 | · | $1.28B | $1.87B | $0 | |
| Current Liabilities | $88.69B | $84.61B | $79.19B | $69.42B | $67.81B | $62.02B | $53.30B | $45.76B | $30.65B | $26.25B | $23.17B | |
| Capital Leases | $13.64B | $14.90B | $16.03B | $16.80B | $18.18B | $18.76B | $18.93B | $18.83B | $306M | · | · | |
| Deferred Tax | $3.83B | $3.81B | $4.31B | $4.02B | $6.27B | $6.79B | $7.29B | $7.74B | $3.00B | $4.21B | $4.22B | |
| Other Non-current Liabilities | $6.77B | $5.43B | $6.21B | $6.73B | $1.90B | $2.35B | $2.16B | $2.26B | $1.28B | $1.55B | $1.54B | |
| Total Liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B | $161.01B | $158.28B | $157.95B | $57.44B | · | · | |
| Long-term Debt | · | · | · | · | · | · | $68.48B | $72.61B | $27.00B | $25.70B | $27.50B | |
| Total Debt | $0 | $2.12B | $200M | · | · | · | $3.78B | · | $27.00B | $27.53B | $27.46B | |
| Common Stock | · | $18M | $18M | $18M | $17M | $17M | $17M | · | $17M | $17M | $17M | |
| Paid-in Capital | · | · | · | · | · | · | · | · | $32.08B | $31.62B | $30.95B | |
| Retained Earnings | $61.20B | $62.84B | $61.60B | $56.40B | $54.91B | $49.64B | $45.11B | $41.09B | $43.56B | $38.98B | $35.51B | |
| Treasury Stock | $36.79B | $36.82B | $33.84B | $31.86B | $28.17B | $28.18B | $28.23B | · | $37.80B | $33.45B | $28.89B | |
| AOCI | $406M | $-120M | $-297M | $-1.26B | $965M | $1.41B | $1.02B | · | $-165M | $-305M | $-358M | |
| Stockholders' Equity | $75.21B | $75.56B | $76.46B | $71.47B | $75.08B | $69.39B | $63.86B | $58.40B | $37.69B | $36.83B | $37.20B | |
| Liabilities + Equity | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B | $230.72B | $222.45B | · | $95.13B | $94.46B | $92.44B | |
| Shares Outstanding | 1,271,000,000 | 1,260,000,000 | 1,288,000,000 | 1,300,000,000 | 1,322,000,000 | 1,310,000,000 | 1,302,000,000 | · | 1,712,000,000 | 1,061,000,000 | 1,101,000,000 |
Грошовий потік
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.61B | $4.60B | $4.37B | $4.22B | $4.49B | $4.44B | $4.37B | · | $2.48B | $2.48B | $2.09B | |
| Stock-based Comp | $535M | $540M | $588M | $447M | $484M | $400M | $453M | · | $234M | $222M | $230M | |
| Deferred Tax | $102M | $-572M | $-676M | $-2.03B | $-402M | $-564M | $-649M | · | $-1.42B | $3M | $-234M | |
| Amort. of Intangibles | $2.00B | $2.00B | $1.90B | $1.80B | $2.20B | $2.30B | $2.40B | · | $817M | $795M | $611M | |
| Restructuring | · | · | · | · | · | · | · | · | $215M | · | · | |
| Other Non-cash | $3.63B | $-72M | $804M | $9.41B | $5.79B | $4.41B | $2.04B | · | $93M | · | · | |
| Operating Cash Flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B | $15.87B | $12.85B | · | $8.01B | $10.14B | $8.54B | |
| CapEx | $2.83B | $2.78B | $3.03B | $2.73B | $2.52B | $2.44B | $2.46B | · | $1.92B | $2.22B | $2.37B | |
| Investing Cash Flow | $-5.87B | $-7.61B | $-20.89B | $-5.05B | $-5.26B | $-5.53B | $-3.34B | · | $-2.88B | $-2.47B | $-13.42B | |
| Debt Issued | $3.97B | $7.91B | $10.90B | $0 | $987M | $9.96B | $3.74B | · | $0 | $3.46B | $14.80B | |
| Net Debt Issued | $340M | $3.14B | $7.73B | $-4.21B | $-9.27B | $-5.67B | $-4.60B | · | · | $-2.49B | $11.90B | |
| Stock Repurchased | $0 | $3.02B | $2.01B | $3.50B | $0 | $0 | $0 | · | $4.36B | $4.46B | $5.00B | |
| Net Stock Activity | $0 | $-3.02B | $-2.01B | $-3.50B | · | · | $0 | · | $-4.36B | $-4.46B | $-5.00B | |
| Dividends Paid | $3.40B | $3.37B | $3.13B | $2.91B | $2.62B | $2.62B | $2.60B | · | $2.05B | $1.84B | $1.58B | |
| Financing Cash Flow | $-4.94B | $-1.14B | $2.68B | $-10.52B | $-11.36B | $-7.70B | $-7.65B | · | $-6.75B | $-6.76B | $4.88B | |
| Net Change in Cash | $-172M | $359M | $-4.78B | $614M | $1.65B | $2.63B | $1.85B | · | $-1.62B | $912M | $-22M | |
| Taxes Paid | $2.17B | $1.70B | $3.52B | $4.12B | $3.19B | $2.93B | $2.72B | · | $2.91B | $3.06B | $3.27B | |
| Free Cash Flow | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B | $13.43B | $10.39B | · | $6.09B | $7.84B | $6.04B | |
| Levered FCF | · | · | $8.40B | $11.76B | $13.85B | $11.29B | $8.15B | · | $5.24B | $7.18B | $5.52B |
Прибутковість
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | · | 15.4% | 16.3% | 17.3% | |
| Operating Margin | 1.2% | 2.3% | 3.8% | 2.4% | 4.5% | 5.2% | 4.7% | · | 5.1% | 5.8% | 6.2% | |
| Net Margin | 0.44% | 1.2% | 2.3% | 1.3% | 2.7% | 2.7% | 2.6% | · | 3.6% | 3.0% | 3.4% | |
| Pretax Margin | 0.53% | 1.7% | 3.1% | 1.8% | 3.6% | 3.6% | 3.5% | · | 4.5% | 4.9% | 5.6% | |
| EBITDA Margin | 2.3% | 3.5% | 5.1% | 3.7% | 6.1% | 6.8% | 6.4% | · | 6.5% | 5.8% | 6.2% | |
| ROA | 0.70% | 1.8% | 3.5% | 1.8% | 3.4% | 3.2% | 3.0% | · | 7.0% | 5.7% | 6.2% | |
| ROE | 2.4% | 6.1% | 11.3% | 5.7% | 10.9% | 10.8% | 10.8% | · | 17.8% | 14.4% | 13.9% | |
| ROIC | 5.0% | 8.2% | 13.4% | 8.1% | 13.3% | 14.8% | 13.1% | · | 11.8% | 9.9% | 8.9% |
Ліквідність та платоспроможність
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | · | 1.0 | 1.2 | 1.3 | |
| Quick Ratio | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.6 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | · | · | · | 0.1 | · | 0.7 | 0.7 | 0.7 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.6 | 0.7 | 0.7 | |
| Interest Coverage | · | · | 5.2 | 3.4 | 5.3 | 4.8 | 3.9 | · | 9.0 | 9.6 | 11.0 |
Ефективність
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.6 | 1.5 | 1.5 | 1.4 | 1.3 | 1.2 | 1.2 | · | 1.9 | 1.9 | 1.8 | |
| Inventory Turnover | 11.8 | 11.4 | 11.7 | 10.7 | 9.7 | 9.1 | 9.3 | · | 10.4 | 10.3 | 9.8 | |
| Receivables Turnover | 10.5 | 10.4 | 11.4 | 12.5 | 12.7 | 13.0 | 13.8 | · | 14.6 | 14.8 | 14.2 |
На акцію
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.18 | $59.97 | $59.36 | $54.63 | $56.79 | $52.97 | $49.05 | · | $37.17 | $34.71 | $33.78 | |
| Revenue / Share | $316.34 | $295.41 | $277.35 | $243.74 | $219.80 | $204.49 | $196.76 | · | $180.43 | $164.53 | $136.14 | |
| Cash Flow / Share | $8.37 | $7.22 | $10.41 | $12.23 | $13.74 | $12.07 | $9.85 | · | $7.82 | $9.33 | $7.47 | |
| Cash / Share | $6.65 | $6.81 | $6.36 | $9.96 | $7.12 | $6.00 | $4.36 | · | $1.67 | $3.18 | $2.23 | |
| Dividend / Share | $2.66 | $2.66 | $2.42 | $2.20 | $2.00 | $2.00 | $2.00 | · | $2.00 | $1.70 | $1.40 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | $2.00 | · | · | |
| EPS (TTM) | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 | $5.46 | $5.08 | · | $6.44 | $4.90 | $4.63 |
Темпи зростання
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.8% | 4.2% | 10.9% | 10.4% | 8.7% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.6% | 8.5% | 10.0% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.4% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -62.0% | -43.4% | 98.5% | -45.9% | 10.3% | · | · | · | · | · | · | |
| EPS CAGR 3Y | -24.7% | -15.3% | 5.8% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -23.9% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -61.7% | -44.7% | 93.5% | -46.1% | 11.5% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -25.7% | -16.8% | 5.1% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -24.4% | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · |
Оцінка (TTM)
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B | $268.71B | $256.78B | · | $184.79B | $177.55B | $153.29B | |
| Net Income TTM | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B | $7.18B | $6.63B | · | $6.62B | $5.32B | $5.24B | |
| Market Cap | $100.87B | $56.56B | $101.70B | $121.15B | $136.38B | $89.47B | $96.73B | · | $73.52B | $83.72B | $107.64B | |
| Enterprise Value | $90.27B | $47.69B | $90.45B | · | · | · | $92.45B | · | $98.71B | $107.80B | $132.56B | |
| P/E | 57.1 | 12.3 | 12.2 | 28.6 | 17.1 | 12.5 | 14.6 | · | 11.3 | 16.1 | 21.1 | |
| P/S | 0.3 | 0.2 | 0.3 | 0.4 | 0.5 | 0.3 | 0.4 | · | 0.4 | 0.5 | 0.7 | |
| P/B | 1.3 | 0.7 | 1.3 | 1.7 | 1.8 | 1.3 | 1.5 | · | 2.0 | 2.3 | 2.9 | |
| P / Cash Flow | 9.5 | 6.2 | 7.6 | 7.5 | 7.5 | 5.6 | 7.5 | · | 9.2 | 8.3 | 12.8 | |
| P / FCF | 12.9 | 8.9 | 9.8 | 9.0 | 8.7 | 6.7 | 9.3 | · | 12.1 | 10.7 | 17.8 | |
| EV / EBITDA | 9.7 | 3.6 | 5.0 | · | · | · | 5.7 | · | 8.2 | 10.4 | 14.0 | |
| EV / FCF | 11.6 | 7.5 | 8.7 | · | · | · | 8.9 | · | 16.2 | 13.7 | 21.9 | |
| EV / Revenue | 0.2 | 0.1 | 0.3 | · | · | · | 0.4 | · | 0.5 | 0.6 | 0.9 | |
| Dividend Yield | 3.4% | 6.0% | 3.1% | 2.4% | 1.9% | 2.9% | 2.7% | · | 2.8% | 2.2% | 1.5% | |
| Earnings Yield | 1.8% | 8.2% | 8.2% | 3.5% | 5.8% | 8.0% | 6.8% | · | 8.9% | 6.2% | 4.7% | |
| Payout Ratio | 192.1% | 73.1% | 37.5% | 70.1% | 33.2% | 36.5% | 39.2% | · | 30.9% | 34.6% | 30.1% | |
| Annual Payout | $3.40B | $3.37B | $3.13B | $2.91B | $2.62B | $2.62B | $2.60B | · | $2.05B | $1.84B | $1.58B |
Звіт про прибутки та збитки
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.10B | $100.43B | $105.69B | $102.87B | $98.92B | $94.59B | $97.71B | $95.43B | $91.23B | $88.44B | $93.81B | $89.76B | $88.92B | $85.28B | $83.85B | $81.16B | |
| Cost of Revenue | $58.86B | $55.44B | $59.06B | $57.05B | $54.01B | $51.06B | $55.27B | $52.95B | $50.00B | $48.07B | $57.42B | $54.69B | $53.54B | $51.45B | $51.73B | $50.37B | |
| Operating Expenses | $101.39B | $95.75B | $103.58B | $106.08B | $96.53B | $91.21B | $95.34B | $94.60B | $88.19B | $86.17B | $90.44B | $86.07B | $85.69B | $81.83B | $80.19B | $85.08B | |
| Operating Income | $4.70B | $4.68B | $2.11B | $-3.21B | $2.38B | $3.37B | $2.37B | $832M | $3.04B | $2.27B | $3.37B | $3.69B | $3.23B | $3.45B | $3.66B | $-3.92B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $716M | · | $693M | $686M | $589M | · | $566M | |
| Other Non-op | $31M | $32M | $29M | $26M | $29M | $28M | $25M | $25M | $24M | $25M | $22M | $22M | $22M | $22M | $43M | $41M | |
| Pretax Income | $3.98B | $3.94B | $1.35B | $-3.48B | $1.65B | $2.62B | $2.13B | $105M | $2.34B | $1.58B | $2.71B | $3.02B | $2.57B | $2.88B | $3.15B | $-4.44B | |
| Income Tax | $982M | $981M | $-1.57B | $508M | $634M | $835M | $503M | $34M | $569M | $456M | $658M | $754M | $656M | $737M | $818M | $-1.04B | |
| Net Income | $2.98B | $2.94B | $2.94B | $-3.98B | $1.02B | $1.78B | $1.64B | $87M | $1.77B | $1.11B | $2.05B | $2.26B | $1.90B | $2.14B | $2.33B | $-3.41B | |
| EPS (Basic) | $2.33 | $2.31 | $2.31 | $-3.13 | $0.81 | $1.41 | $1.31 | $0.07 | $1.41 | $0.88 | $1.59 | $1.76 | $1.48 | $1.66 | $1.78 | $-2.59 | |
| EPS (Diluted) | $2.31 | $2.30 | $2.31 | $-3.13 | $0.80 | $1.41 | $1.30 | $0.07 | $1.41 | $0.88 | $1.59 | $1.75 | $1.48 | $1.65 | $1.79 | $-2.59 | |
| Shares (Basic) | 1,279,000,000 | 1,273,000,000 | · | 1,269,000,000 | 1,266,000,000 | 1,261,000,000 | · | 1,259,000,000 | 1,256,000,000 | 1,260,000,000 | · | 1,287,000,000 | 1,283,000,000 | 1,283,000,000 | · | 1,315,000,000 | |
| Shares (Diluted) | 1,287,000,000 | 1,279,000,000 | · | 1,269,000,000 | 1,270,000,000 | 1,264,000,000 | · | 1,259,000,000 | 1,259,000,000 | 1,267,000,000 | · | 1,290,000,000 | 1,287,000,000 | 1,291,000,000 | · | 1,315,000,000 | |
| EBITDA | $5.83B | $5.79B | · | $-2.07B | $3.55B | $4.53B | · | $832M | $3.04B | $3.41B | · | $3.69B | $3.23B | $4.45B | · | $-3.93B |
Баланс
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.33B | $9.54B | $8.45B | $9.10B | $11.79B | $10.08B | $8.59B | $6.88B | $12.51B | $9.80B | $8.20B | $13.04B | $13.81B | $14.62B | $12.95B | $17.20B | |
| Short-term Investments | $2.63B | $2.26B | $2.15B | $2.13B | $2.39B | $2.58B | $2.41B | $2.81B | $3.75B | $3.29B | · | $3.15B | $3.08B | $3.10B | · | $2.79B | |
| Receivables | $40.31B | $40.99B | $39.78B | $43.86B | $40.65B | $39.62B | $36.47B | $36.18B | $32.38B | $32.22B | · | $32.93B | $29.55B | $28.33B | · | $26.32B | |
| Inventory | $17.62B | $17.77B | $19.25B | $18.96B | $17.45B | $17.39B | $18.11B | $17.65B | $16.07B | $16.35B | · | $17.95B | $17.29B | $18.26B | · | $18.06B | |
| Other Current Assets | $3.46B | $4.25B | $5.09B | $3.06B | $3.38B | $3.53B | $3.08B | $3.83B | $5.24B | $5.82B | · | $3.07B | $3.41B | $3.77B | · | $2.48B | |
| Current Assets | $75.35B | $74.82B | $74.71B | $77.11B | $75.65B | $73.19B | $68.64B | $67.34B | $69.95B | $67.47B | · | $70.14B | $67.76B | $68.71B | · | $68.34B | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $13.02B | $13.00B | $12.87B | · | $12.63B | |
| Goodwill | $85.48B | $85.48B | $85.48B | $85.48B | $91.20B | $91.20B | $91.27B | $91.27B | $91.27B | $91.27B | $91.27B | $91.26B | $91.26B | $84.06B | $78.15B | $78.09B | |
| Intangibles | $24.64B | $25.07B | $25.51B | $25.98B | $26.22B | $26.57B | $27.32B | $27.82B | $28.31B | $28.77B | · | $29.62B | $30.12B | $26.37B | · | $25.16B | |
| Other Non-current Assets | $7.43B | $7.42B | $5.12B | $5.16B | $5.21B | $5.23B | $4.79B | $4.76B | $4.80B | $4.80B | · | $4.83B | $4.85B | $4.82B | · | $4.85B | |
| Total Assets | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B | $253.22B | $252.43B | $252.48B | $249.74B | · | $251.31B | $250.07B | $239.33B | · | $231.21B | |
| Accrued Liabilities | $22.48B | $22.26B | $22.39B | $23.41B | $23.10B | $22.37B | $20.81B | $20.17B | $21.16B | $22.35B | · | $22.57B | $22.83B | $21.52B | · | $19.42B | |
| Short-term Debt | · | · | $0 | $1.25B | $3.04B | $1.26B | $2.12B | $800M | $0 | $2.72B | · | · | $1.00B | · | · | · | |
| Current Liabilities | $87.04B | $86.41B | $88.69B | $92.69B | $94.16B | $88.96B | $84.61B | $84.63B | $81.39B | $83.32B | · | $81.55B | $79.21B | $75.05B | · | $72.41B | |
| Capital Leases | $12.98B | $13.33B | $13.64B | $14.01B | $14.33B | $14.59B | $14.90B | $15.26B | $15.54B | $15.74B | · | $16.44B | $16.61B | $16.57B | · | $17.17B | |
| Deferred Tax | $3.77B | $3.77B | $3.83B | $3.55B | $3.60B | $3.66B | $3.81B | $3.63B | $4.05B | $4.18B | · | $4.25B | $4.59B | $4.09B | · | $3.51B | |
| Other Non-current Liabilities | $6.11B | $6.71B | $4.78B | $4.76B | $4.78B | $5.42B | $5.43B | $5.48B | $5.53B | $6.21B | · | $6.24B | $6.32B | $6.67B | · | $6.77B | |
| Total Liabilities | $173.87B | $175.34B | $178.16B | $182.22B | $180.79B | $178.47B | $177.49B | $177.32B | $177.37B | $175.59B | · | $176.80B | $177.07B | $167.75B | · | $160.20B | |
| Total Debt | · | · | · | $1.25B | $3.04B | $1.26B | · | $800M | $0 | $2.72B | · | · | $1.00B | · | · | · | |
| Common Stock | · | · | · | $18M | $18M | $18M | · | $18M | $18M | $18M | · | $18M | $18M | $18M | $18M | $18M | |
| Retained Earnings | $65.40B | $63.28B | $61.20B | $59.11B | $63.94B | $63.77B | $62.84B | $62.04B | $62.80B | $61.87B | · | $60.34B | $58.87B | $57.75B | · | $54.57B | |
| Treasury Stock | $36.85B | $36.71B | $36.79B | $36.78B | $36.85B | $36.73B | $36.82B | $36.81B | $36.92B | $36.77B | · | $33.83B | $33.93B | $33.80B | · | $30.33B | |
| AOCI | $188M | $201M | $406M | $416M | $272M | $59M | $-120M | $209M | $-319M | $-341M | · | $-1.00B | $-858M | $-875M | · | $-1.61B | |
| Stockholders' Equity | $79.70B | $77.46B | $75.21B | $72.93B | $77.38B | $76.93B | $75.56B | $74.94B | $74.93B | $73.97B | · | $74.34B | $72.73B | $71.38B | · | $70.68B | |
| Liabilities + Equity | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B | $253.22B | $252.43B | $252.48B | $249.74B | · | $251.31B | $250.07B | $239.33B | · | $231.21B | |
| Shares Outstanding | 1,278,000,000 | 1,273,000,000 | 1,271,000,000 | 1,270,000,000 | 1,267,000,000 | 1,262,000,000 | 1,260,000,000 | 1,258,000,000 | 1,256,000,000 | 1,252,000,000 | · | 1,287,000,000 | 1,282,000,000 | 1,279,000,000 | · | 1,315,000,000 |
Грошовий потік
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.13B | $1.11B | $1.15B | $1.13B | $1.17B | $1.15B | $1.15B | $1.16B | $1.15B | $1.14B | $1.13B | $1.13B | $1.10B | $1.00B | $1.04B | $1.04B | |
| Stock-based Comp | $176M | $266M | $135M | $138M | $136M | $126M | $137M | $133M | $133M | $137M | $127M | $154M | $204M | $103M | $106M | $105M | |
| Amort. of Intangibles | $431M | $442M | $507M | $500M | $494M | $499M | $478M | $507M | $507M | $508M | $504M | $509M | $485M | $402M | $420M | $458M | |
| Other Non-cash | · | $-75M | · | · | · | $1.50B | · | · | · | $2.52B | · | · | · | $4.20B | · | · | |
| Operating Cash Flow | $6.34B | $4.25B | $3.39B | $796M | $1.90B | $4.56B | $1.86B | $-745M | $3.09B | $4.90B | $-2.64B | $2.72B | $5.91B | $7.44B | $-1.95B | $9.12B | |
| CapEx | $691M | $849M | $784M | $698M | $607M | $743M | $768M | $670M | $638M | $705M | $911M | $545M | $591M | $984M | $688M | $580M | |
| Investing Cash Flow | $-1.88B | $-874M | $-2.00B | $-2.09B | $-1.02B | $-762M | $-547M | $-3.35B | $-1.62B | $-2.09B | $-1.24B | $-771M | $-10.36B | $-8.51B | $-119M | $-805M | |
| Debt Issued | · | · | $0 | $3.97B | · | · | $2.95B | $0 | $4.96B | $0 | $0 | $0 | $4.95B | $5.95B | $0 | $0 | |
| Net Debt Issued | · | $-1.52B | · | · | · | $-743M | · | · | · | $-18M | · | · | · | $5.59B | · | · | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $-1M | $-3M | $3.03B | $-1M | $-3M | $-2M | $2.02B | $1.50B | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3.03B | · | · | · | $-2.02B | · | · | |
| Dividends Paid | $878M | $847M | $845M | $846M | $866M | $840M | $838M | $837M | $858M | $840M | $779M | $779M | $795M | $779M | $719M | $726M | |
| Financing Cash Flow | $-2.69B | $-2.32B | $-2.03B | $-1.38B | $806M | $-2.33B | $431M | $-1.59B | $1.25B | $-1.23B | $-972M | $-2.70B | $3.63B | $2.73B | $-2.19B | $-3.22B | |
| Net Change in Cash | $1.77B | $1.06B | $-640M | $-2.67B | $1.68B | $1.46B | $1.74B | $-5.68B | $2.71B | $1.58B | $-4.85B | $-752M | $-828M | $1.65B | $-4.26B | $5.10B | |
| Taxes Paid | $374M | $-337M | $998M | $305M | $725M | $138M | $274M | $700M | $666M | $63M | $908M | $837M | $1.70B | $75M | $1.05B | $1.18B | |
| Free Cash Flow | · | $3.40B | · | · | · | $3.81B | · | · | · | $4.20B | · | · | · | $6.45B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $3.69B | · | · | · | $6.02B | · | · |
Прибутковість
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 4.4% | 4.7% | · | -3.1% | 2.4% | 3.6% | · | 0.87% | 3.3% | 2.6% | · | 4.1% | 3.6% | 4.0% | · | -4.8% | |
| Net Margin | 2.8% | 2.9% | · | -3.9% | 1.0% | 1.9% | · | 0.09% | 1.9% | 1.3% | · | 2.5% | 2.1% | 2.5% | · | -4.2% | |
| Pretax Margin | 3.8% | 3.9% | · | -3.4% | 1.7% | 2.8% | · | 0.11% | 2.6% | 1.8% | · | 3.4% | 2.9% | 3.4% | · | -5.5% | |
| EBITDA Margin | 5.5% | 5.8% | · | -2.0% | 3.6% | 4.8% | · | 0.87% | 3.3% | 3.9% | · | 4.1% | 3.6% | 5.2% | · | -4.8% | |
| ROA | 1.2% | 1.2% | · | -1.6% | 0.40% | 0.70% | · | 0.03% | 0.70% | 0.46% | · | 0.94% | 0.79% | 0.90% | · | -1.5% | |
| ROE | 3.8% | 3.8% | · | -5.4% | 1.3% | 2.4% | · | 0.12% | 2.4% | 1.5% | · | 3.1% | 2.6% | 2.9% | · | -4.7% | |
| ROIC | 4.4% | 4.5% | · | -5.0% | 1.8% | 2.9% | · | 0.74% | 3.1% | 2.1% | · | 3.7% | 3.3% | 3.6% | · | -4.2% |
Ліквідність та платоспроможність
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.9 | 0.9 | 0.9 | · | 0.9 | |
| Quick Ratio | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.5 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | 0.0 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.2 | · | 5.3 | 4.7 | 5.9 | · | -6.9 |
Ефективність
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Inventory Turnover | 3.4 | 3.2 | · | 3.1 | 3.2 | 3.0 | · | 3.0 | 3.0 | 2.8 | · | 3.0 | 3.1 | 2.8 | · | 2.8 | |
| Receivables Turnover | 2.6 | 2.5 | · | 2.6 | 2.7 | 2.6 | · | 2.8 | 2.9 | 2.9 | · | 3.0 | 3.1 | 3.1 | · | 3.1 |
На акцію
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $62.36 | $60.85 | · | $57.42 | $61.07 | $60.96 | · | $59.57 | $59.66 | $59.08 | · | $57.76 | $56.73 | $55.81 | · | $53.75 | |
| Revenue / Share | $82.44 | $78.52 | · | $81.06 | $77.89 | $74.83 | · | $75.80 | $72.47 | $69.80 | · | $69.58 | $69.09 | $66.06 | · | $61.72 | |
| Cash Flow / Share | · | $3.32 | · | · | · | $3.60 | · | · | · | $3.87 | · | · | · | $5.76 | · | · | |
| Cash / Share | $8.86 | $7.50 | · | $7.16 | $9.30 | $7.98 | · | $5.46 | $9.96 | $7.83 | · | $10.13 | $10.77 | $11.43 | · | $13.08 | |
| Dividend / Share | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.60 | $0.60 | $0.60 | $0.60 | $0.55 | $0.55 | |
| EPS (TTM) | $3.79 | $2.28 | · | $0.38 | $3.58 | $4.19 | · | $3.95 | $5.63 | $5.70 | · | $6.67 | $2.33 | $3.14 | · | $2.51 |
Оцінка (TTM)
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $415.09B | $407.90B | · | $394.08B | $386.64B | $378.96B | · | $368.91B | $363.25B | $360.94B | · | $347.81B | $339.20B | $330.92B | · | $315.23B | |
| Net Income TTM | $4.89B | $2.93B | · | $469M | $4.53B | $5.28B | · | $5.02B | $7.19B | $7.32B | · | $8.63B | $2.96B | $4.09B | · | $3.37B | |
| Market Cap | $132.21B | $91.43B | · | $95.75B | $87.40B | $85.50B | · | $79.10B | $74.18B | $99.86B | · | $89.86B | $88.62B | $95.04B | · | $125.41B | |
| Enterprise Value | · | · | · | $85.76B | $76.26B | $74.11B | · | $70.22B | $57.92B | $89.49B | · | · | $72.74B | · | · | · | |
| P/E | 27.3 | 31.5 | · | 198.4 | 19.3 | 16.2 | · | 15.9 | 10.5 | 14.0 | · | 10.5 | 29.7 | 23.7 | · | 38.0 | |
| P/S | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.4 | |
| P/B | 1.7 | 1.2 | · | 1.3 | 1.1 | 1.1 | · | 1.1 | 1.0 | 1.4 | · | 1.2 | 1.2 | 1.3 | · | 1.8 | |
| P / Cash Flow | · | 21.5 | · | · | · | 18.8 | · | · | · | 20.4 | · | · | · | 12.8 | · | · | |
| EV / Revenue | · | · | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | · | 0.2 | · | · | · | |
| Dividend Yield | 2.6% | 3.7% | · | 3.5% | 3.9% | 4.0% | · | 4.2% | 4.4% | 3.2% | · | 3.4% | 3.4% | 3.1% | · | 2.3% | |
| Earnings Yield | 3.7% | 3.2% | · | 0.50% | 5.2% | 6.2% | · | 6.3% | 9.5% | 7.1% | · | 9.6% | 3.4% | 4.2% | · | 2.6% | |
| Payout Ratio | · | 28.8% | · | · | · | 47.2% | · | · | · | 75.5% | · | · | · | 36.5% | · | · | |
| Annual Payout | $3.42B | $3.40B | · | $3.39B | $3.38B | $3.37B | · | $3.31B | $3.26B | $3.19B | · | $3.07B | $3.02B | $2.96B | · | $2.85B |
Найновіший період ліворуч · нульові значення показані як ·
Фінансова звітність Звіт про прибутки та збитки, баланс, рух грошових коштів — річні, за останні 5 років
| Метрика | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Виручка | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B |
| Операційна маржа % | 1.2% | 2.3% | 3.8% | 2.4% | 4.5% |
| Чистий прибуток | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B |
| Розбавлений EPS | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 |
| Метрика | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Борг / Власний капітал | 0.0 | 0.0 | 0.0 | · | · |
| Поточний коефіцієнт | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 |
| Коефіцієнт швидкої ліквідності | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 |
| Метрика | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Вільний грошовий потік | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B |
Інституційні власники (13F) 2 274 подавачі звітності · $125.7B всього · Станом на 30 вересня 2026 р.
Інституційні інвестори, які звітують про володіння цими акціями у своїй квартальній формі SEC 13F. Тільки довгі позиції; один подавець звітності може з'явитися двічі для окремих опціонних контрактів. Великі протилежні опціонні позиції (пут/кол) зазвичай відображають маркет-мейкінг або хеджування запасів, а не спрямованість переконань.
| Нові позиції | Закриті позиції | Збільшено | Зменшено | Зміна чистих акцій |
|---|---|---|---|---|
| 314 (+117 проти попереднього кв.) | 93 (-96 проти попереднього кв.) | 799 (+75 проти попереднього кв.) | 755 (-20 проти попереднього кв.) | +50.0M |
Порівняно з Q1 2026. Звіти SEC Form 13F подаються протягом 45 днів після закінчення кварталу плюс невеликий буфер для тих, хто подає із запізненням — квартали, що ще знаходяться в цьому вікні, пропускаються на користь останньої повністю звітної пари.
| Інституційний інвестор | Вартість | Акції | % від відстежуваного 13F | Тип |
|---|---|---|---|---|
| BlackRock, Inc. | $12 747 461 705 | 123 223 409 | 10,14% | Акції |
| VANGUARD GROUP INC | $9 579 508 282 | 120 709 530 | 7,62% | Акції |
| VANGUARD CAPITAL MANAGEMENT LLC | $8 618 974 924 | 83 315 369 | 6,86% | Акції |
| Capital World Investors | $7 753 834 783 | 74 951 955 | 6,17% | Акції |
| STATE STREET CORP | $6 236 318 558 | 60 283 408 | 4,96% | Акції |
| Dodge & Cox | $5 173 820 539 | 50 012 765 | 4,12% | Акції |
| WELLINGTON MANAGEMENT GROUP LLP | $3 496 725 140 | 33 801 113 | 2,78% | Акції |
| GEODE CAPITAL MANAGEMENT, LLC | $3 079 404 427 | 29 899 653 | 2,45% | Акції |
| FMR LLC | $2 991 837 927 | 28 920 617 | 2,38% | Акції |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 755 624 444 | 26 637 259 | 2,19% | Акції |
| Capital Research Global Investors | $2 516 851 376 | 24 329 151 | 2,00% | Акції |
| BANK OF AMERICA CORP /DE/ | $2 398 868 007 | 23 188 670 | 1,91% | Акції |
| JPMORGAN CHASE & CO | $2 290 461 677 | 22 112 970 | 1,82% | Акції |
| Invesco Ltd. | $2 130 597 379 | 20 595 431 | 1,70% | Акції |
| MORGAN STANLEY | $1 924 793 937 | 18 606 028 | 1,53% | Акції |
| NORGES BANK | $1 866 126 481 | 18 038 922 | 1,49% | Акції |
| Capital International Investors | $1 591 868 430 | 15 387 600 | 1,27% | Акції |
| GOLDMAN SACHS GROUP INC | $1 387 451 459 | 13 411 807 | 1,10% | Акції |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1 371 677 011 | 13 259 314 | 1,09% | Акції |
| Davis Selected Advisers | $1 227 594 458 | 11 865 916 | 0,98% | Акції |
| PZENA INVESTMENT MANAGEMENT LLC | $1 217 558 500 | 11 769 536 | 0,97% | Акції |
| NORTHERN TRUST CORP | $1 186 760 815 | 11 471 830 | 0,94% | Акції |
| FRANKLIN RESOURCES INC | $1 032 982 350 | 9 985 330 | 0,82% | Акції |
| Legal & General Group Plc | $948 946 746 | 9 172 999 | 0,76% | Акції |
| Bank of New York Mellon Corp | $932 453 862 | 9 013 571 | 0,74% | Акції |
| Clearbridge Investments, LLC | $883 116 767 | 8 536 952 | 0,70% | Акції |
| ROYAL BANK OF CANADA | $880 475 000 | 8 511 113 | 0,70% | Акції |
| GQG Partners LLC | $822 989 370 | 7 955 411 | 0,65% | Акції |
| AMERIPRISE FINANCIAL INC | $821 911 618 | 7 943 034 | 0,65% | Акції |
| Amundi | $778 468 900 | 7 525 080 | 0,62% | Акції |
| DIMENSIONAL FUND ADVISORS LP | $763 688 490 | 7 381 983 | 0,61% | Акції |
| VANGUARD FIDUCIARY TRUST CO | $741 242 940 | 7 165 229 | 0,59% | Акції |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $595 969 397 | 8 298 098 | 0,47% | Акції |
| Nuveen, LLC | $544 750 652 | 5 265 836 | 0,43% | Акції |
| UBS Group AG | $544 267 107 | 5 261 161 | 0,43% | Акції |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $524 415 257 | 5 069 263 | 0,42% | Акції |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $511 339 969 | 4 942 871 | 0,41% | Акції |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $499 125 457 | 4 824 799 | 0,40% | Акції |
| CITADEL ADVISORS LLC | $497 856 229 | 4 812 530 | 0,40% | Акції |
| DEUTSCHE BANK AG\ | $466 633 571 | 4 510 716 | 0,37% | Акції |
| RAYMOND JAMES FINANCIAL INC | $449 870 951 | 4 348 680 | 0,36% | Акції |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $409 796 485 | 3 961 300 | 0,33% | Опціон кол |
| Allianz Asset Management GmbH | $391 245 314 | 3 781 975 | 0,31% | Акції |
| WELLS FARGO & COMPANY/MN | $380 921 357 | 3 682 178 | 0,30% | Акції |
| VIKING GLOBAL INVESTORS LP | $378 974 695 | 3 663 361 | 0,30% | Акції |
| Swiss National Bank | $371 195 152 | 3 588 160 | 0,30% | Акції |
| National Pension Service | $352 166 145 | 3 404 216 | 0,28% | Акції |
| Mitsubishi UFJ Asset Management Co., Ltd. | $322 653 390 | 3 118 927 | 0,26% | Акції |
| Russell Investments Group, Ltd. | $312 682 898 | 3 022 292 | 0,25% | Акції |
| Holocene Advisors, LP | $310 524 210 | 3 001 684 | 0,25% | Акції |
Активісти та власники %+ 5 1 холдинг
Інвестори, які подали Розклад SEC 13D — бенефіціарна власність понад 5% з наміром вплинути на емітента (активістські частки, кампанії в раді директорів, M&A). Кожен рядок показує останній відомий стан позиції цього подавця.
| Подавець | Подано | Частка | Статус | Мета | Подача |
|---|---|---|---|---|---|
| CVS Caremark Corporation | 07 січня 2011 р. | · | Первинна подача | M&A / продаж | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Інсайдери компанії 86 інсайдерів · 48 керівники · 41 директори
| Інсайдер | Роль | Остання активність | Кількість акцій у власності | Купівлі за 12 міс. | Продажі за 12 міс. | Нетто 12 міс |
|---|---|---|---|---|---|---|
| David J. Joyner | President, CEO and Chair | 01 квітня 2026 р. F | 70 349 | 0 | 0 | $0 |
| Karen S Lynch | President and CEO | 01 квітня 2024 р. A | 74 687 | 0 | 0 | $0 |
| Brian Newman | EVP, Chief Financial Officer | 31 травня 2026 р. F | 3 008 | 0 | 0 | $0 |
| Thomas F. Cowhey | EVP and CFO | 01 квітня 2025 р. A | 41 109 | 0 | 0 | $0 |
| Shawn M Guertin | EVP & Chief Financial Officer | 01 квітня 2023 р. A | 34 706 | 0 | 0 | $0 |
| Eva C Boratto | EVP & CFO | 04 травня 2021 р. S | 115 331 | 0 | 0 | $0 |
| David M Denton | EVP and CFO | 29 листопада 2018 р. S | 403 | 0 | 0 | $0 |
| David B Rickard | Chief Financial Officer | 14 грудня 2009 р. M | 207 179 | 0 | 0 | $0 |
| Howard A Mclure | President, Caremark Pharm Serv | 02 листопада 2009 р. M | 0 | 0 | 0 | $0 |
| Jonathan C Roberts | EVP & Chief Operating Officer | 01 квітня 2022 р. A | 426 025 | 0 | 0 | $0 |
| James David Clark | SVP, Cont & Chief Acct Officer | 26 червня 2026 р. F | 27 606 | 0 | 0 | $0 |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 31 травня 2026 р. F | 9 557 | 0 | 0 | $0 |
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 08 травня 2026 р. S | 10 133 | 0 | 1 | $-6 230 379 |
| Prem S Shah | EVP and Group President | 31 березня 2026 р. A | 64 356 | 0 | 0 | $0 |
| Heidi B Capozzi | EVP and Chief People Officer | 31 березня 2026 р. A | 13 023 | 3 | 0 | $4 588 |
| Samrat S. Khichi | EVP, CPO and General Counsel | 31 березня 2026 р. A | 33 421 | 0 | 0 | $0 |
| Steven H Nelson | EVP and President, Aetna | 31 березня 2026 р. A | 2 900 | 1 | 0 | $1 289 |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 квітня 2024 р. A | 23 666 | 0 | 0 | $0 |
| Laurie P. Havanec | EVP and Chief People Officer | 01 квітня 2024 р. A | 9 426 | 0 | 0 | $0 |
| Brian A Kane | EVP/President, Aetna | 01 квітня 2024 р. A | 12 569 | 0 | 0 | $0 |
| Finke Daniel P | EVP/Pres, Health Care Benefits | 01 квітня 2023 р. A | 35 068 | 0 | 0 | $0 |
| Michelle A Peluso | EVP and Co-President of Retail | 01 квітня 2023 р. A | 124 383 | 0 | 0 | $0 |
| Thomas M Moriarty | EVP & General Counsel | 31 грудня 2022 р. F | 315 273 | 0 | 0 | $0 |
| Alan Lotvin | EVP&President-PharmacyServices | 04 серпня 2022 р. M | 109 183 | 0 | 0 | $0 |
| Troyen A Brennan | EVP and Chief Medical Officer | 03 квітня 2022 р. F | 232 676 | 0 | 0 | $0 |
| Neela Montgomery | EVP and Pres., Pharmacy/Retail | 01 квітня 2021 р. A | 29 502 | 0 | 0 | $0 |
| Lisa Bisaccia | Former EVP & Chief HR Officer | 01 квітня 2021 р. F | 66 417 | 0 | 0 | $0 |
| Joshua Matthew Flum | EVP, ENT STRATEGY & DIGITAL | 28 лютого 2021 р. F | 25 657 | 0 | 0 | $0 |
| Jonathan E. Mayhew | EVP - Transformation | 02 грудня 2020 р. F | 6 855 | 0 | 0 | $0 |
| Derica W Rice | EVP & President, CVS Caremark | 28 лютого 2020 р. F | 26 827 | 0 | 0 | $0 |
| Kevin Hourican | EVP & President, CVS Pharmacy | 01 квітня 2019 р. A | 15 237 | 0 | 0 | $0 |
| Helena Foulkes | EVP & President-CVS Pharmacy | 16 лютого 2018 р. M | 45 107 | 0 | 0 | $0 |
| Robert O. Kraft | EVP and President - Omnicare | 03 квітня 2017 р. A | 92 360 | 0 | 0 | $0 |
| Andrew Sussman | EVP, Clinical Services | 03 квітня 2017 р. A | 16 433 | 0 | 0 | $0 |
| Stephen J Gold | EVP & CIO | 03 квітня 2017 р. A | 46 818 | 0 | 0 | $0 |
| Per Gh Lofberg | EVP | 02 січня 2015 р. M | 23 419 | 0 | 0 | $0 |
| Mark Cosby | EVP & President-CVS/pharmacy | 30 вересня 2013 р. M | 45 955 | 0 | 0 | $0 |
| Laird Daniels | SVP, Cont & Chief Acct Officer | 01 квітня 2013 р. A | 17 845 | 0 | 0 | $0 |
| Douglas A Sgarro | EVP and CLO | 11 травня 2012 р. M | 214 | 0 | 0 | $0 |
| Stuart M Mcguigan | SVP and CIO | 16 березня 2012 р. M | 10 967 | 0 | 0 | $0 |
| Thomas M Ryan | Non-Executive Chairman | 03 квітня 2011 р. F | 1 156 702 | 0 | 0 | $0 |
| Sara Finley | SVP, Gen Counsel | 18 лютого 2011 р. F | 29 053 | 0 | 0 | $0 |
| Michael V Ferdinandi | Senior Vice President | 19 серпня 2009 р. S | 16 021 | 0 | 0 | $0 |
| Paula A Price | Controller | 12 лютого 2008 р. A | 16 498 | 0 | 0 | $0 |
| Edwin M Crawford | Chairman | 29 жовтня 2007 р. A | 135 572 | 0 | 0 | $0 |
| William R Spalding | EVP Caremark Pharmacy Services | 18 червня 2007 р. M | 182 | 0 | 0 | $0 |
| Gregory S Weishar | Vice President | 03 квітня 2006 р. A | 30 161 | 0 | 0 | $0 |
| Larry D Solberg | Senior Vice President | 16 лютого 2006 р. A | 5 978 | 0 | 0 | $0 |
| ROBBINS LARRY | Директор | 21 травня 2026 р. S | 4 824 799 | 0 | 8 | $-352 750 556 |
| Fernando Aguirre | Директор | 21 травня 2026 р. D | 10 513 | 0 | 0 | $0 |
| Jeffrey R. Balser | Директор | 14 травня 2026 р. A | 15 717 | 0 | 0 | $0 |
| Douglas H. Shulman | Директор | 14 травня 2026 р. A | 5 929 | 0 | 0 | $0 |
| Leslie V Norwalk | Директор | 14 травня 2026 р. A | 7 376 | 0 | 0 | $0 |
| Michael F Mahoney | Директор | 14 травня 2026 р. A | 6 345 | 0 | 0 | $0 |
| Anne A. Finucane | Директор | 14 травня 2026 р. A | 591 | 0 | 0 | $0 |
| John E Gallina | Директор | 14 травня 2026 р. A | 582 | 0 | 0 | $0 |
| Guy P Sansone | Директор | 14 травня 2026 р. A | 15 106 | 0 | 0 | $0 |
| Scott J Kirby | Директор | 14 травня 2026 р. A | 14 434 | 0 | 0 | $0 |
| DECOUDREAUX ALECIA A | Директор | 14 травня 2026 р. A | 2 970 | 0 | 0 | $0 |
| David C Brown II | Директор | 14 травня 2026 р. A | 129 316 | 0 | 0 | $0 |
| Roger N Farah | Директор | 30 листопада 2025 р. F | 19 438 | 0 | 0 | $0 |
| Mary L Schapiro | Директор | 21 листопада 2024 р. A | 7 585 | 0 | 0 | $0 |
| Jean Pierre Millon | Директор | 21 листопада 2024 р. A | 4 514 | 0 | 0 | $0 |
| Nancy Ann Deparle | Директор | 21 листопада 2024 р. A | 34 169 | 0 | 0 | $0 |
| Edward J Ludwig | Директор | 02 травня 2024 р. P | 21 630 | 0 | 0 | $0 |
| William C Weldon | Директор | 17 листопада 2022 р. A | 1 591 | 0 | 0 | $0 |
| Tony L White | Директор | 11 травня 2022 р. A | 37 852 | 0 | 0 | $0 |
| David W Dorman | Директор | 11 травня 2022 р. A | 109 875 | 0 | 0 | $0 |
| Larry J Merlo | Директор | 31 травня 2021 р. F | 632 313 | 0 | 0 | $0 |
| Mark T Bertolini | Директор | 20 листопада 2019 р. A | 13 773 | 0 | 0 | $0 |
| Richard M Bracken | Директор | 20 листопада 2019 р. A | 15 348 | 0 | 0 | $0 |
| Richard J Swift | Директор | 20 листопада 2019 р. A | 7 336 | 0 | 0 | $0 |
| Kristen Gibney Williams | Директор | 09 травня 2013 р. A | 1 695 | 0 | 0 | $0 |
| C A Piccolo | Директор | 14 грудня 2012 р. S | 181 461 | 0 | 0 | $0 |
| Marian L Heard | Директор | 08 листопада 2012 р. A | 11 346 | 0 | 0 | $0 |
| Edwin M Banks | Директор | 15 березня 2012 р. M | 23 187 | 0 | 0 | $0 |
| Terrence Murray | Директор | 02 листопада 2011 р. A | 84 140 | 0 | 0 | $0 |
| Sheli Z Rosenberg | Директор | 04 листопада 2010 р. A | 125 112 | 0 | 0 | $0 |
| JOYCE WILLIAM H | Директор | 04 листопада 2010 р. A | 18 390 | 0 | 0 | $0 |
| Roger L Headrick | Директор | 23 травня 2007 р. P | 2 200 | 0 | 0 | $0 |
| Alfred J Verrecchia | Директор | 07 березня 2007 р. A | 0 | 0 | 0 | $0 |
| Don W Cornwell | Директор | 22 грудня 2006 р. A | · | 0 | 0 | $0 |
| Thomas P Gerrity | Директор | 09 листопада 2006 р. A | 68 460 | 0 | 0 | $0 |
| Stanley P Goldstein | Директор | 11 травня 2006 р. J | 590 967 | 0 | 0 | $0 |
| Terry R Lautenbach | Директор | 21 травня 2004 р. A | 27 915 | 0 | 0 | $0 |
| Chris W Bodine | · | 18 лютого 2009 р. A | 23 132 | 0 | 0 | $0 |
Інсайдери згідно з формами SEC 3/4/5; чистий результат = лише відкритий ринок купівлі/продажу
Присутність в ETF Належить 157 ETF
Вага відображає лише прямі акціонерні володіння (N-PORT); фонди з кредитним плечем або похідними інструментами можуть мати додаткову експозицію за свопами, яка не відображається.
| Фонд | Вага | Одиниці | Станом на | Джерело |
|---|---|---|---|---|
| IHF · iShares Trust | 13,37% | 1 839 467 SH | 11 вересня 2026 р. | Щоденно |
| DUSA · Davis Fundamental ETF Trust | 5,28% | 642 932 NS | 31 липня 2026 р. | N-PORT |
| GEND · Spinnaker ETF Series | 4,47% | 2 080 NS | 31 липня 2026 р. | N-PORT |
| IYK · iShares Trust | 4,25% | 617 818 SH | 11 вересня 2026 р. | Щоденно |
| CVGD · Elevation Series Trust | 4,14% | 54 893 NS | 31 липня 2026 р. | N-PORT |
| PEZ · Invesco Exchange-Traded Fund Trust | 3,42% | 8 582 SH | 01 жовтня 2026 р. | Щоденно |
| FMTM · EA Series Trust | 3,17% | 76 503 NS | 31 липня 2026 р. | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 2,83% | 2 458 NS | 31 липня 2026 р. | N-PORT |
| DWLD · Davis Fundamental ETF Trust | 2,70% | 158 312 NS | 31 липня 2026 р. | N-PORT |
| SPDV · ETF Series Solutions | 2,29% | 28 879 NS | 31 липня 2026 р. | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,94% | 3 824 297 SH | 19 серпня 2026 р. | Щоденно |
| FHLC · FIDELITY COVINGTON TRUST | 1,92% | 605 189 NS | 31 липня 2026 р. | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 1,92% | 2 169 744 SH | 01 жовтня 2026 р. | Щоденно |
| RPV · Invesco Exchange-Traded Fund Trust | 1,77% | 339 241 SH | 01 жовтня 2026 р. | Щоденно |
| REVS · Columbia ETF Trust I | 1,68% | 53 828 NS | 31 липня 2026 р. | N-PORT |
| IXJ · iShares Trust | 1,54% | 670 400 SH | 11 вересня 2026 р. | Щоденно |
| CURE · Direxion Shares ETF Trust | 1,53% | 25 107 NS | 31 липня 2026 р. | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,47% | 149 525 SH | 01 жовтня 2026 р. | Щоденно |
| PWV · Invesco Exchange-Traded Fund Trust | 1,41% | 298 497 SH | 01 жовтня 2026 р. | Щоденно |
| SPVM · Invesco Exchange-Traded Fund Trust | 1,39% | 21 140 SH | 01 жовтня 2026 р. | Щоденно |
| DVY · iShares Trust | 1,37% | 3 384 928 SH | 11 вересня 2026 р. | Щоденно |
| VLUE · iShares Trust | 1,35% | 1 359 538 SH | 11 вересня 2026 р. | Щоденно |
| CVAR · ETF Opportunities Trust | 1,21% | 4 966 NS | 31 липня 2026 р. | N-PORT |
| GURU · Global X Funds | 1,19% | 6 951 NS | 31 липня 2026 р. | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 1,13% | 40 514 000 | 01 жовтня 2026 р. | Щоденно |
| RECS · Columbia ETF Trust I | 1,09% | 610 992 NS | 31 липня 2026 р. | N-PORT |
| VRP · Invesco Exchange-Traded Fund Trust … | 1,06% | 31 397 000 | 01 жовтня 2026 р. | Щоденно |
| FEUS · FlexShares Trust | 0,97% | 10 395 NS | 31 липня 2026 р. | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,95% | 77 895 SH | 19 серпня 2026 р. | Щоденно |
| EQWL · Invesco Exchange-Traded Fund Trust | 0,92% | 295 291 SH | 01 жовтня 2026 р. | Щоденно |
| FXG · First Trust Exchange-Traded AlphaDE… | 0,82% | 18 035 NS | 31 липня 2026 р. | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,81% | 90 308 SH | 01 жовтня 2026 р. | Щоденно |
| LSEQ · Harbor ETF Trust | 0,80% | 1 171 NS | 31 липня 2026 р. | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | 0,80% | 190 028 NS | 31 липня 2026 р. | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,75% | 50 750 SH | 19 серпня 2026 р. | Щоденно |
| MTUM · iShares Trust | 0,75% | 1 909 551 SH | 11 вересня 2026 р. | Щоденно |
| UPSD · ETF Series Solutions | 0,74% | 8 286 NS | 31 липня 2026 р. | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,72% | 12 142 NS | 31 липня 2026 р. | N-PORT |
| WLDR · Two Roads Shared Trust | 0,71% | 6 228 NS | 31 липня 2026 р. | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,70% | 20 507 000 | 01 жовтня 2026 р. | Щоденно |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,67% | 31 259 000 | 01 жовтня 2026 р. | Щоденно |
| CATH · Global X Funds | 0,63% | 78 905 NS | 31 липня 2026 р. | N-PORT |
| GSY · Invesco Actively Managed Exchange-T… | 0,63% | 24 935 000 | 01 жовтня 2026 р. | Щоденно |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,62% | 1 682 074 SH | 01 жовтня 2026 р. | Щоденно |
| MGV · VANGUARD WORLD FUND | 0,62% | 801 966 SH | 19 серпня 2026 р. | Щоденно |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 36 106 NS | 31 липня 2026 р. | N-PORT |
| FFLV · FIDELITY COVINGTON TRUST | 0,57% | 900 NS | 31 липня 2026 р. | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,55% | 715 000 | 01 жовтня 2026 р. | Щоденно |
| VYM · VANGUARD WHITEHALL FUNDS | 0,55% | 5 122 611 SH | 19 серпня 2026 р. | Щоденно |
| PDP · Invesco Exchange-Traded Fund Trust | 0,51% | 86 857 SH | 01 жовтня 2026 р. | Щоденно |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,50% | 40 184 NS | 31 липня 2026 р. | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,49% | 12 134 319 SH | 19 серпня 2026 р. | Щоденно |
| DFUV · Dimensional ETF Trust | 0,48% | 710 848 NS | 31 липня 2026 р. | N-PORT |
| DFLV · Dimensional ETF Trust | 0,47% | 302 533 NS | 31 липня 2026 р. | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,46% | 529 245 SH | 01 жовтня 2026 р. | Щоденно |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,46% | 13 367 000 | 30 вересня 2026 р. | Щоденно |
| IWX · iShares Trust | 0,45% | 185 452 SH | 11 вересня 2026 р. | Щоденно |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,45% | 293 814 SH | 19 серпня 2026 р. | Щоденно |
| IVE · iShares Trust | 0,41% | 2 119 397 SH | 11 вересня 2026 р. | Щоденно |
| DIVB · iShares Trust | 0,41% | 87 120 SH | 11 вересня 2026 р. | Щоденно |
| CHRI · Global X Funds | 0,41% | 310 NS | 31 липня 2026 р. | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 17 702 NS | 31 липня 2026 р. | N-PORT |
| IUSV · iShares Trust | 0,39% | 1 116 077 SH | 11 вересня 2026 р. | Щоденно |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,37% | 774 792 SH | 19 серпня 2026 р. | Щоденно |
| ESG · FlexShares Trust | 0,37% | 4 650 NS | 31 липня 2026 р. | N-PORT |
| ILCV · iShares Trust | 0,35% | 49 213 SH | 11 вересня 2026 р. | Щоденно |
| IWD · iShares Trust | 0,33% | 2 852 019 SH | 11 вересня 2026 р. | Щоденно |
| GLBL · Pacer Funds Trust | 0,32% | 34 NS | 31 липня 2026 р. | N-PORT |
| EGLE · Global X Funds | 0,31% | 65 NS | 31 липня 2026 р. | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,30% | 57 429 SH | 19 серпня 2026 р. | Щоденно |
| OEF · iShares Trust | 0,26% | 540 125 SH | 11 вересня 2026 р. | Щоденно |
| INFO · Harbor ETF Trust | 0,25% | 20 350 NS | 31 липня 2026 р. | N-PORT |
| MGC · VANGUARD WORLD FUND | 0,25% | 255 122 SH | 19 серпня 2026 р. | Щоденно |
| ESGV · VANGUARD WORLD FUND | 0,23% | 290 253 SH | 19 серпня 2026 р. | Щоденно |
| TOPC · iShares Trust | 0,23% | 777 SH | 11 вересня 2026 р. | Щоденно |
| IWL · iShares Trust | 0,22% | 49 933 SH | 11 вересня 2026 р. | Щоденно |
| VV · VANGUARD INDEX FUNDS | 0,21% | 1 490 162 SH | 19 серпня 2026 р. | Щоденно |
| XYLD · Global X Funds | 0,21% | 64 877 NS | 31 липня 2026 р. | N-PORT |
| XTR · Global X Funds | 0,21% | 96 NS | 31 липня 2026 р. | N-PORT |
| XVV · iShares Trust | 0,21% | 14 653 SH | 11 вересня 2026 р. | Щоденно |
| EUSA · iShares, Inc. | 0,21% | 41 666 SH | 11 вересня 2026 р. | Щоденно |
| XRMI · Global X Funds | 0,21% | 990 NS | 31 липня 2026 р. | N-PORT |
| PTLC · Pacer Funds Trust | 0,21% | 64 355 NS | 31 липня 2026 р. | N-PORT |
| DFSU · Dimensional ETF Trust | 0,21% | 44 781 NS | 31 липня 2026 р. | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 174 338 NS | 31 липня 2026 р. | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,20% | 106 735 NS | 31 липня 2026 р. | N-PORT |
| XYLG · Global X Funds | 0,20% | 1 250 NS | 31 липня 2026 р. | N-PORT |
| VOTE · TCW ETF Trust | 0,20% | 21 382 NS | 31 липня 2026 р. | N-PORT |
| ADME · ETF Series Solutions | 0,20% | 5 697 NS | 31 липня 2026 р. | N-PORT |
| XCLR · Global X Funds | 0,20% | 69 NS | 31 липня 2026 р. | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,20% | 33 144 255 SH | 19 серпня 2026 р. | Щоденно |
| TOV · EA Series Trust | 0,20% | 5 061 NS | 31 липня 2026 р. | N-PORT |
| ACIO · ETF Series Solutions | 0,20% | 44 949 NS | 31 липня 2026 р. | N-PORT |
| LRGF · iShares Trust | 0,20% | 76 567 SH | 11 вересня 2026 р. | Щоденно |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,20% | 37 793 SH | 01 жовтня 2026 р. | Щоденно |
| DFUS · Dimensional ETF Trust | 0,19% | 389 482 NS | 31 липня 2026 р. | N-PORT |
| VOXP · Advisors Series Trust | 0,19% | 108 NS | 31 липня 2026 р. | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,19% | 4 814 NS | 31 липня 2026 р. | N-PORT |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,19% | 212 337 SH | 19 серпня 2026 р. | Щоденно |
| QDPL · Pacer Funds Trust | 0,19% | 30 732 NS | 31 липня 2026 р. | N-PORT |
| EVUS · iShares Trust | 0,19% | 7 499 SH | 11 вересня 2026 р. | Щоденно |
| IVV · iShares Trust | 0,19% | 16 082 099 SH | 11 вересня 2026 р. | Щоденно |
| RSP · Invesco Exchange-Traded Fund Trust | 0,18% | 2 050 840 SH | 01 жовтня 2026 р. | Щоденно |
| SIZE · iShares Trust | 0,18% | 8 166 SH | 11 вересня 2026 р. | Щоденно |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,18% | 27 242 NS | 31 липня 2026 р. | N-PORT |
| ILCB · iShares Trust | 0,18% | 24 548 SH | 11 вересня 2026 р. | Щоденно |
| VTI · VANGUARD INDEX FUNDS | 0,18% | 40 509 855 SH | 19 серпня 2026 р. | Щоденно |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,18% | 108 067 SH | 19 серпня 2026 р. | Щоденно |
| IWB · iShares Trust | 0,17% | 888 287 SH | 11 вересня 2026 р. | Щоденно |
| IYY · iShares Trust | 0,17% | 54 746 SH | 11 вересня 2026 р. | Щоденно |
| USCL · iShares Trust | 0,17% | 50 655 SH | 11 вересня 2026 р. | Щоденно |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,17% | 22 631 NS | 31 липня 2026 р. | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,17% | 7 610 SH | 01 жовтня 2026 р. | Щоденно |
| IWV · iShares Trust | 0,17% | 354 060 SH | 11 вересня 2026 р. | Щоденно |
| TILT · FlexShares Trust | 0,17% | 34 918 NS | 31 липня 2026 р. | N-PORT |
| DCOR · Dimensional ETF Trust | 0,17% | 53 112 NS | 31 липня 2026 р. | N-PORT |
| DFAU · Dimensional ETF Trust | 0,17% | 197 043 NS | 31 липня 2026 р. | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,17% | 220 176 SH | 01 жовтня 2026 р. | Щоденно |
| ITOT · iShares Trust | 0,17% | 1 661 154 SH | 11 вересня 2026 р. | Щоденно |
| HCMT · Direxion Shares ETF Trust | 0,16% | 8 880 NS | 31 липня 2026 р. | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,16% | 15 076 SH | 01 жовтня 2026 р. | Щоденно |
| ACVF · ETF Opportunities Trust | 0,16% | 2 271 NS | 31 липня 2026 р. | N-PORT |
| DYNF · BlackRock ETF Trust | 0,16% | 675 214 SH | 11 вересня 2026 р. | Щоденно |
| SPXL · Direxion Shares ETF Trust | 0,15% | 99 749 NS | 31 липня 2026 р. | N-PORT |
| TOK · iShares Trust | 0,14% | 3 579 SH | 11 вересня 2026 р. | Щоденно |
| PHDG · Invesco Actively Managed Exchange-T… | 0,14% | 1 007 SH | 01 жовтня 2026 р. | Щоденно |
| URTH · iShares, Inc. | 0,13% | 114 536 SH | 11 вересня 2026 р. | Щоденно |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,13% | 70 355 SH | 01 жовтня 2026 р. | Щоденно |
| DFAC · Dimensional ETF Trust | 0,12% | 539 188 NS | 31 липня 2026 р. | N-PORT |
| ACWI · iShares Trust | 0,12% | 406 018 SH | 11 вересня 2026 р. | Щоденно |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,11% | 1 069 623 SH | 19 серпня 2026 р. | Щоденно |
| DXUV · Dimensional ETF Trust | 0,10% | 5 157 NS | 31 липня 2026 р. | N-PORT |
| QLC · FlexShares Trust | 0,09% | 8 960 NS | 31 липня 2026 р. | N-PORT |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,08% | 1 368 NS | 31 липня 2026 р. | N-PORT |
| CRBN · iShares Trust | 0,05% | 6 619 SH | 11 вересня 2026 р. | Щоденно |
| FBCG · FIDELITY COVINGTON TRUST | 0,05% | 35 048 NS | 31 липня 2026 р. | N-PORT |
| GLOF · iShares Trust | 0,02% | 478 SH | 11 вересня 2026 р. | Щоденно |
| LGDX · Tidal Trust III | 0,02% | 251 NS | 31 липня 2026 р. | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,02% | 21 000 | 01 жовтня 2026 р. | Щоденно |
| GTO · Invesco Actively Managed Exchange-T… | 0,01% | 419 000 | 01 жовтня 2026 р. | Щоденно |
| PEVC · Pacer Funds Trust | 0,01% | 3 NS | 31 липня 2026 р. | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0,01% | 600 000 SH | 11 вересня 2026 р. | Щоденно |
| DFVX · Dimensional ETF Trust | 0,01% | 517 NS | 31 липня 2026 р. | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 липня 2026 р. | Щоденно |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 липня 2026 р. | Щоденно |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 липня 2026 р. | Щоденно |
| VCEB · VANGUARD WORLD FUND | · | · | 30 липня 2026 р. | Щоденно |
CVS Консенсус аналітиків Бичачі та ведмежі думки аналітиків, 12-місячна цільова ціна, потенціал зростання
12-місячна цільова ціна
25 аналітиків · 2026-09-28Середня цільова ціна $116.28 +34,5%
Порівняння з аналогами (підгалузь GICS) Ключові показники порівняно з аналогами в секторі
База за фінансовий рік, ціни на момент закриття останнього фінансового року кожної компанії.
| Тікер | Капіталізація | P/E | Виручка рік до року | Чиста маржа | ROE | Валова маржа |
|---|---|---|---|---|---|---|
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
Останні новини Останні заголовки, що згадують цю компанію
Торгові сигнали Останні сигнали купівлі/продажу із зазначенням ціни входу та коефіцієнта ризику/прибутку
Зараз немає активних сигналів — жодна картка не заповнена, і це чесно.
Мої показники Ваш персональний список спостереження — вибрані рядки з Повних фундаментальних даних
Виберіть показники, які для вас важливі — натисніть + поруч із будь-яким рядком у розділі Повна фундаментальна інформація вище.
Ваш вибір збережено і він буде застосовуватися до всіх тікерів.